Hemodynamic Changes Induced by Liposomes and Liposome-Encapsulated Hemoglobin in Pigs
- 4 May 1999
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 99 (17), 2302-2309
- https://doi.org/10.1161/01.cir.99.17.2302
Abstract
Background—Intravenous administration of some liposomal drugs can trigger immediate hypersensitivity reactions that include symptoms of cardiopulmonary distress. The mechanism underlying the cardiovascular changes has not been clarified. Methods and Results—Anesthetized pigs (n=18) were injected intravenously with 5-mg boluses of large multilamellar liposomes, and the ensuing hemodynamic, hematologic, and laboratory changes were recorded. The significant (P2. These changes peaked between 1 and 5 minutes after injection, subsided within 10 to 20 minutes, were lipid dose–dependent (ED50=4.5±1.4 mg), and were quantitatively reproducible in the same animal several times over 7 hours. The liposome-induced rises of pulmonary arterial pressure showed close quantitative and temporal correlation with elevations of plasma thromboxane B2 and were inhibited by an anti-C5a monoclonal antibody (GS1), by sCR1, or by indomethacin. Liposomes caused C5a production in pig serum in vitro through classic pathway activation and bound IgG and IgM natural antibodies. Zymosan- and hemoglobin-containing liposomes and empty liposomes caused essentially identical pulmonary changes. Conclusions—The intense, nontachyphylactic, highly reproducible, complement-mediated pulmonary hypertensive effect of minute amounts of intravenous liposomes in pigs represents a unique, unexplored phenomenon in circulation physiology. The model provides highly sensitive detection and study of cardiopulmonary side effects of liposomal drugs and many other pharmaceutical products due to “complement activation–related pseudoallergy” (CARPA).Keywords
This publication has 25 references indexed in Scilit:
- Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunctionThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Complement activation in vitro by the red cell substitute, liposome- encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1Transfusion, 1997
- Unbedenklichkeitsaspekte bei der Anwendung von pegyliertem liposomalem Doxorubicin bei KrebspatientenDrugs, 1997
- LiposomenDrugs, 1997
- Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodiesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1996
- Profound Normovolemic HemodilutionAnesthesia & Analgesia, 1996
- Complement Activation in Rats by Liposomes and Liposome-Encapsulated Hemoglobin: Evidence for Anti-lipid Antibodies and Alternative Pathway ActivationBiochemical and Biophysical Research Communications, 1994
- Anaphylactic reactions to liposomal amphotericinThe Lancet, 1994
- Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and NecrosisScience, 1990
- ASSOCIATION OF COMPLEMENT ACTIVATION AND ELEVATED PLASMA-C5a WITH ADULT RESPIRATORY DISTRESS SYNDROMEThe Lancet, 1980